为风湿与肌肉骨骼疾病中的足踝疾病制定核心结局集:范围综述与OMERACT 2022足踝特别兴趣小组会议报告
该范围综述从150项符合条件的成人风湿与肌肉骨骼疾病足踝疾病研究中提取结局域,并按OMERACT Filter 2.1分类。足踝疼痛是最常测量的结局域(78%的研究)。2022年10月虚拟OMERACT特别兴趣小组会议讨论了综述发现并收集了关于核心结局集范围与后续步骤的反馈。
要点
- 足踝疼痛是风湿与肌肉骨骼疾病足踝研究中测量最多的结局域(78%的研究)。
- 多数研究纳入足踝骨关节炎(63%)或类风湿关节炎足踝受累(29%)的参与者。
- 其他结局域在表现、生活影响及社会/资源使用等核心领域存在相当大的异质性。
核心结论
- 范围综述的发现和特别兴趣小组的反馈将有助于为风湿与肌肉骨骼疾病中的足踝疾病制定核心结局集。
- 后续步骤是确定哪些结局域对患者重要,然后与关键利益相关者进行德尔菲练习以优先排序结局域。
研究设计与样本
- 进行范围综述以识别现有文献中的结局域。
- 纳入标准为比较药物、保守或手术干预的临床试验和观察性研究,涉及患有类风湿关节炎、骨关节炎、脊柱关节炎、晶体性关节病和结缔组织病中任何足或踝疾病的成人参与者。
- 结局域根据OMERACT Filter 2.1进行分类。
主要发现
- 从150项符合条件的研究中提取结局域。
- 大多数研究纳入足/踝骨关节炎参与者(63%的研究)或类风湿关节炎足/踝受累参与者(29%的研究)。
- 足/踝疼痛是最常测量的结局域(78%的研究),是所有风湿与肌肉骨骼疾病中最常指定的结局域。
- 其他测量的结局域在表现(体征、症状、生物标志物)、生活影响和社会/资源使用等核心领域存在相当大的异质性。
关键数值与推荐
- 足/踝疼痛是78%的研究中测量的结局域。
- 63%的研究纳入足/踝骨关节炎参与者,29%的研究纳入类风湿关节炎足/踝受累参与者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Foot and ankle involvement is common in rheumatic and musculoskeletal diseases, yet high-quality evidence assessing the effectiveness of treatments for these disorders is lacking. The Outcome Measures in Rheumatology (OMERACT) Foot and Ankle Working Group is developing a core outcome set for use in clinical trials and longitudinal observational studies in this area. METHODS: A scoping review was performed to identify outcome domains in the existing literature. Clinical trials and observational studies comparing pharmacological, conservative or surgical interventions involving adult participants with any foot or ankle disorder in the following rheumatic and musculoskeletal diseases (RMDs) were eligible for inclusion: rheumatoid arthritis (RA), osteoarthritis (OA), spondyloarthropathies, crystal arthropathies and connective tissue diseases. Outcome domains were categorised according to the OMERACT Filter 2.1. RESULTS: Outcome domains were extracted from 150 eligible studies. Most studies included participants with foot/ankle OA (63% of studies) or foot/ankle involvement in RA (29% of studies). Foot/ankle pain was the outcome domain most commonly measured (78% of studies), being the most frequently specified outcome domain across all RMDs. There was considerable heterogeneity in the other outcome domains measured, across core areas of manifestations (signs, symptoms, biomarkers), life impact, and societal/resource use. The group's progress to date, including findings from the scoping review, was presented and discussed during a virtual OMERACT Special Interest Group (SIG) in October 2022. During this meeting, feedback was sought amongst delegates regarding the scope of the core outcome set, and feedback was received on the next steps of the project, including focus group and Delphi methods. CONCLUSION: Findings from the scoping review and feedback from the SIG will contribute to the development of a core outcome set for foot and ankle disorders in RMDs. The next steps are to determine which outcome domains are important to patients, followed by a Delphi exercise with key stakeholders to prioritise outcome domains.
引用
- Chapman LS, Jones J, Redmond AC, et al. Developing a core outcome set for foot and ankle disorders in rheumatic and musculoskeletal diseases: A scoping review and report from the OMERACT 2022 foot and ankle special interest group session. Semin Arthritis Rheum. 2023. PMID: 37156170. doi:10.1016/j.semarthrit.2023.152210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。